BioSpace News Archive

Toronto, Ontario--(Newsfile Corp. - January 8, 2021) - Relay Medical Corp. (CSE: RELA) (OTCQB: RYMDF) (FSE: EIY2) (“Relay” or the “Company”), is pleased to announce that further to its press release of December 18, 2020, the Company has completed the first tranche of its non-brokered private placement financing (the “Offering”) through the issuance of 25,375,000 units (each, a “Unit”) at a price of $0.20 per Unit for gross proceeds of $5,075,000.

BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that Jay M. Short , Ph.D., Chief Executive Officer, and Scott Smith , President, with participation by other BioAtla executives, will present at the 39 th Annual J.P. Mor

Qosina recently added 12 new filter options for fluid and gas applications. The company’s extensive filter product line includes a variety of hydrophilic and hydrophobic filters, transducer protectors, and an assortment of NRFit™ filters that comply with the ISO 80369-6 standard. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210108005537/en/ Qosina

39th Annual JP Morgan Healthcare Conference 23rd Annual Needham Growth Conference

Graphite Bio, a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced that Josh Lehrer, M.Phil, M.D., chief executive officer, will present an overview of Graphite Bio’s corporate strategy, business priorities and upcoming clinical milestones at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11,